Business
Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Full Topline Data on Track for Q4 2023
Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disord...
About this update from Cybin, Inc.
[{"type":"text","content":"\n \n \n \n Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Full Topline Data on Track for Q4 2023\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen3{\nVERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; PADDING-LEFT:0.17em; PADDING-RIGHT:0.17em; BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; BORDER-BOTTOM:black 0pt; BORDER-LEFT:black 0pt\n}\n.prngen2{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: BOTTOM; BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; BORDER-BOTTOM:black 0pt; BORDER-LEFT:black 0pt\n}\n.prnml4{\nMARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n - Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale (\"MADRS\") score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) -\n \n \n \n \n - For reference, pooled data from 232 industry studies of current standard of care antidepressants,\n \n s\n \n elective serotonin reuptake inhibitors (SSRIs)\n \n \n , submitted to U.S. Food and Drug Administration (\"FDA\") (Stone et al, 2022) show an average improvement of 1.82 points vs. placebo -\n \n \n \n \n - Robust response and remission three weeks after single dose, with 53.3% of patients responding and 20% of patients in remission (no longer meeting the clinical definition of depression) vs. 0% for placebo -\n \n \n \n \n - Favorable safety and tolerability profile with no treatment-related serious adverse events at 12 mg dose -\n \n \n \n \n - Company to host conference call to discuss CYB003 interim results on\n \n Wednesday, November 1, 2023\n \n at\n \n 11:00 a.m. ET\n \n –\n \n \n \n \n This news release constitutes a \"designated news release\" for the p...